Enterprise Value

168.3M

Cash

236.8M

Avg Qtr Burn

-24.96M

Short % of Float

16.92%

Insider Ownership

5.01%

Institutional Own.

73.63%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
XPOVIO (Selinexor) (XPO1 inhibitor) Details
Multiple myeloma, Diffuse large B cell lymphoma, Cancer

Approved

Quarterly sales

Phase 3

Data readout

Phase 3

Data readout

Eltanexor Details
Colorectal cancer , Prostate cancer, Multiple myeloma, Myelodysplastic syndrome

Phase 2

Update

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

XPOVIO (Selinexor) (XPO1 inhibitor) Details
Rare diseases, Liposarcoma, Cancer

Failed

Discontinued

Failed

Discontinued